Elan Corporation News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

27.07.11	Elan Reports Second Quarter and First Half 2011 Financial Results (Businesswire)
13.07.11	ShareLuxe Club in Kyoto and Bali Selects Interval International (Businesswire)
01.06.11	Elan to Present at Jefferies 2011 Global Healthcare Conference (Businesswire)
20.04.11	Elan Reports First Quarter 2011 Financial Results (Businesswire)
25.03.11	Elan Announces Filing of Annual Report for Year Ended December 31, 2010 (Businesswire)
13.10.10	Fiserv Announces Closing of Offer to Purchase Its Outstanding 6.125% Senior Notes Due 2012 (Businesswire)
08.06.10	FDA hat Sicherheitsfragen zur MS-Mittel Glenenia von Novartis (Dow Jones)
11.01.10	Weltbekannter Yogi Baron Baptiste enthüllt neues Programm, das Menschen mit Multipler Sklerose helfen soll. (Businesswire)
29.10.09	Elan Corporation Plc Announces Expiration of Tender Offer for 7¾% Senior Fixed Rate Notes Due 2011 (Businesswire)
27.10.09	Subset Data from Two Randomized Phase 3 Trials Show TYSABRI Significantly Reduces Rates of Hospitalization in Patients with Moderate-to-Severe Crohn’s Disease (Businesswire)
21.10.09	Elan Reports Third Quarter 2009 Financial Results (Businesswire)
21.09.09	ROUNDUP/Aktien Europa: Schwächer - Gewinnmitnahmen belasten - Impulse fehlen (dpa-afx)
13.07.09	Elan and Transition Therapeutics Announce Phase 1 Data Showing ELND005 Achieves Desired Concentrations in Brain Tissue and Cerebrospinal Fluid (Businesswire)
23.10.08	Elan Reports Third Quarter 2008 Financial Results (Businesswire)
22.07.08	Biogen Idec und Elan feiern zweiten Jahrestag von TYSABRI(R) zur Behandlung von Multipler Sklerose (Businesswire)
24.04.08	Elan Reports First Quarter 2008 Financial Results (Businesswire)
10.09.07	Scotland Advises TYSABRI(R) Use in Highly Active Relapsing Remitting Multiple Sclerosis (PR Newswire)
09.08.07	Dr. Lars Ekman, President of Research and Development, Transitions to Board of Director Role (Businesswire)
02.07.07	TYSABRI(R) Recommended by NICE for Use in Highly Active Relapsing Remitting Multiple Sclerosis in the Final Appraisal Determination (Businesswire)
24.04.07	Elan Reports First Quarter 2007 Financial Results (Businesswire)
10.04.07	Elan Announces Commencement of Exchange Offer for US$615 Million Aggregate Principal Amount of Notes (Businesswire)
20.02.07	Elan Reports Fourth Quarter and Full-Year 2006 Financial Results (Businesswire)
26.12.06	Seven Summits Research Releases Alerts on F, CVS, ELN, PGR, and LTD (PR Newswire)
22.11.06	Elan Announces Completion of Offering of US$615 Million Aggregate Principal Amount of Senior Notes (Businesswire)
06.10.06	New Pharmacoeconomic Data on TYSABRI(R) Demonstrate Significant Reduction in Steroid Use and Hospitalizations in Patients with Multiple Sclerosis (Businesswire)
29.09.06	Neue Daten belegen auf dem MS-Kongress ECTRIMS bedeutende Verbesserungen der kognitiven Fähigkeiten bei Patienten mit Multipler Sklerose (Businesswire)
28.09.06	New Data on TYSABRI(R) Presented at ECTRIMS Congress Demonstrate Significant Improvement in Cognitive Function in Patients with Multiple Sclerosis (Businesswire)
01.08.06	Elan Reports Second Quarter 2006 Financial Results (Businesswire)
24.07.06	Biogen Idec und Elan geben Lieferbarkeit von TYSABRI(R) zur Behandlung wiederkehrender Formen von multipler Sklerose bekannt (Businesswire)
24.07.06	Biogen Idec and Elan Announce Availability of TYSABRI(R) for the Treatment of Relapsing Forms of Multiple Sclerosis (Businesswire)
06.07.06	Elan Signs License Agreement with Abbott for Elan's Proprietary NanoCrystal(R) Technology; To Develop a Single Fixed-Dose Combination of TriCor(R) and Crestor(R) for High Cholesterol Patients (Businesswire)
29.06.06	TYSABRI(R) erhält Zulassung in der Europäischen Union für die Behandlung rezidivierend-remittierender Formen multipler Sklerose (Businesswire)
29.06.06	TYSABRI(R) Receives Approval in European Union for the Treatment of Relapsing Remitting Forms of Multiple Sclerosis (Businesswire)
26.05.06	Elan Announces the Appointment of a New Board Director (Businesswire)
25.05.06	Elan Holds Its AGM, All Resolutions Passed (Businesswire)
07.04.06	Neue Daten zu TYSABRI(R) zeigen signifikante Effekte auf gesundheitsbezogene Lebensqualität bei Patienten mit multipler Sklerose (Businesswire)
30.03.06	Biogen Idec und Elan kündigen Wiederaufnahme der Gabe von TYSABRI(R) zur MS-Behandlung im Rahmen von klinischen Studien an (Businesswire)
09.03.06	FDA-Beratergremium empfiehlt einheitlich die Wiedereinführung von TYSABRI® zur Behandlung rezidivierender Formen der multiplen Sklerose (Businesswire)
06.02.06	Elan meldet Finanzergebnisse des vierten Quartals und des Gesamtjahres 2005 (Businesswire)
23.12.05	Elan gibt Präsentationen auf medizinischen Fachkonferenzen im Januar 2006 (Businesswire)
27.10.05	Elan Reports Third Quarter 2005 Financial Results (Businesswire)
26.07.05	Institute for the Study of Aging Invites Scientists to Apply for New Alzheimer's Drug Discovery Research Grant Program (PR Newswire)
06.07.05	Par Pharmaceutical Announces FDA Approval of Megace(R) ES for Anorexia, Cachexia, or an Unexplained, Significant Weight Loss in Patients With a Diagnosis of AIDS (PR Newswire)
30.06.05	Phase-III-Induktionsstudie mit TYSABRI(R) bei Morbus Crohn erfüllt primären Endpunkt; TYSABRI bewirkt statistisch signifikantes Ansprechen und Remission bei Patienten mit aktiver Krankheit (Businesswire)
02.06.05	Elan tilgt über 240 Mio. USD der Verbindlichkeiten bis 2008 (Businesswire)
01.06.05	Elan meldet Ernennung neuer Vorstandsmitglieder (Businesswire)
27.05.05	FDA Grants Approval to Market Focalin XR(TM) for the Treatment of ADHD in Adults, Adolescents and Children (PR Newswire)
02.05.05	MORNING UPDATE: Man Securities Inc. issues alerts for ELN, TOY, ZRAN, (PR Newswire)
13.04.05	Positive One-Year Data From SENTINEL Trial Evaluating Addition of TYSA (Businesswire)
13.04.05	TYSABRI Two-Year Monotherapy Data Support Positive One-Year Efficacy F (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Holcim	94.20	3.65 %	K V
UBS Group	30.16	3.64 %	K V
Sika	233.30	2.73 %	K V
Geberit	517.00	2.25 %	K V
Part Grp Hldg	1’418.00	1.61 %	K V
Alcon	83.58	-0.29 %	K V
CieFinRichemont	176.90	-0.45 %	K V
Sonova Hldg	306.50	-0.81 %	K V
Novartis	97.71	-0.88 %	K V
Roche Hldg G	287.70	-1.24 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Elan Corporation PLC (spons. ADRs)

Aktien Top/Flop

Meistgelesene Nachrichten